Hypermarcas (OTCMKTS:HYPMY) Shares Gap Down – Should You Sell?

Shares of Hypermarcas (OTCMKTS:HYPMY) gapped down prior to trading on Wednesday . The stock had previously closed at $4.85, but opened at $4.62. Hypermarcas shares last traded at $4.62, with a volume of 634 shares changing hands.

Hypermarcas Stock Performance

The stock has a fifty day simple moving average of $4.36 and a two-hundred day simple moving average of $4.46. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.80 and a current ratio of 1.26. The stock has a market cap of $2.92 billion, a price-to-earnings ratio of 20.04 and a beta of 0.82.

Hypermarcas (OTCMKTS:HYPMY) last posted its quarterly earnings results on Wednesday, November 12th. The company reported $0.13 earnings per share for the quarter. Hypermarcas had a net margin of 12.03% and a return on equity of 6.99%. The company had revenue of $408.83 million for the quarter.

About Hypermarcas

Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.